BTIG maintains Coya Therapeutics stock buy rating, $15 target
BTIG analysts upheld their Buy rating and $15.00 price target for Coya Therapeutics (NASDAQ:COYA), following recent clinical trial data. The stock, currently trading at $7.11, has shown strong ...
FierceBiotech7d
Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
Medscape8d
Investigative Treatments for Moderate to Severe Psoriasis Reviewed
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
Too Old to Operate2d
GR and Inflammatory Pathways in Chronic Chagasic Cardiomyopathy
The following is a summary of “Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for ...
β-glucans show promise as adjuvants for allergy treatment
A recent study carried out by a research team from the Paul-Ehrlich-Institut investigated the immunomodulating properties of ...
Medscape9d
Morning Macrophage Activity Optimizes Inflammation Control
Aligning therapies with the biologic clock may improve efficacy, as macrophage activity peaks early in the morning, worsening inflammatory disease symptoms.
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...
News Medical on MSN14m
Chronic inflammation's connection to atrial fibrillation points to IL-1β as a promising treatment target
A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...
News Medical on MSN6d
Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model
Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.
HCW Biologics receives clearance of IND from FDA for HCW9302
HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...
Healio5d
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.